The elevation of ANA against histone H1 or HMGB1 in PBC patients [116,117] and the elevation of biliary HMGB1 in PSC patients [118] also suggest that histone H1 and HMGB1 may act as a potential therapeutic target in autoimmune liver diseases. This evidence concerns the gene HMGB1 and pancreatic serous cystadenoma.